Literature DB >> 32575418

Hot Spot TERT Promoter Mutations Are Rare in Sporadic Pancreatic Neuroendocrine Neoplasms and Associated with Telomere Length and Epigenetic Expression Patterns.

Alexandra Posch1, Sarah Hofer-Zeni1, Eckhard Klieser2, Florian Primavesi3, Elisabeth Naderlinger1, Anita Brandstetter1, Martin Filipits1, Romana Urbas4, Stefan Swiercynski5, Tarkan Jäger5, Paul Winkelmann2, Tobias Kiesslich6, Lingeng Lu7, Daniel Neureiter2, Stefan Stättner3,8, Klaus Holzmann1.   

Abstract

Cancer cells activate a telomere maintenance mechanism like telomerase in order to proliferate indefinitely. Telomerase can be reactivated by gain-of-function Telomerase Reverse Transcriptase (TERT) promoter mutations (TPMs) that occur in several cancer subtypes with high incidence and association with diagnosis, prognosis and epigenetics. However, such information about TPMs in sporadic pancreatic neuroendocrine neoplasms (pNENs) including tumor (pNET) and carcinoma (pNEC) is less well defined. We have studied two hot spot TPMs and telomere length (TL) in pNEN and compared the results with clinicopathological information and proliferation-associated miRNA/HDAC expression profiles. DNA was isolated from formalin-fixed paraffin-embedded (FFPE) tissue of 58 sporadic pNEN patients. T allele frequency of C250T and C228T TPM was analyzed by pyrosequencing, relative TL as telomeric content by qPCR. In total, five pNEN cases (9%) including four pNETs and one pNEC were identified with TPMs, four cases with exclusive C250T as predominant TPM and one case with both C250T and C228T. T allele frequencies of DNA isolated from adjacent high tumor cell content FFPE tissue varied considerably, which may indicate TPM tumor heterogeneity. Overall and disease-free survival was not associated with TPM versus wild-type pNEN cases. Binary category analyses indicated a marginally significant relationship between TPM status and longer telomeres (p = 0.086), and changes in expression of miR449a (p = 0.157), HDAC4 (p = 0.146) and HDAC9 (p = 0.149). Future studies with larger patient cohorts are needed to assess the true clinical value of these rare mutations in pNEN.

Entities:  

Keywords:  TERT promoter mutation; histone deacetylase; microRNA; pancreatic neuroendocrine tumor; pyrosequencing; telomere length; tumor heterogeneity

Year:  2020        PMID: 32575418     DOI: 10.3390/cancers12061625

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  1 in total

Review 1.  Global mapping of cancers: The Cancer Genome Atlas and beyond.

Authors:  Carlo Ganini; Ivano Amelio; Riccardo Bertolo; Pierluigi Bove; Oreste Claudio Buonomo; Eleonora Candi; Chiara Cipriani; Nicola Di Daniele; Hartmut Juhl; Alessandro Mauriello; Carla Marani; John Marshall; Sonia Melino; Paolo Marchetti; Manuela Montanaro; Maria Emanuela Natale; Flavia Novelli; Giampiero Palmieri; Mauro Piacentini; Erino Angelo Rendina; Mario Roselli; Giuseppe Sica; Manfredi Tesauro; Valentina Rovella; Giuseppe Tisone; Yufang Shi; Ying Wang; Gerry Melino
Journal:  Mol Oncol       Date:  2021-07-20       Impact factor: 6.603

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.